

## DAFTAR PUSTAKA

- Agustin, R., Ratih, H., 2015. Profil Disolusi Tablet Sustained Release Natrium Diklofenak dengan Menggunakan Matriks Metolose 90 SH 4000. *J. Sains Farm. Klin.* 1, 176.
- Ahammad, T., Begum, M., Towheedur Rahman, A.F.M., Hasan, M., Paul, S.R., Eamen, S., Hussain, Md.I., Ali, Md.H., Islam, Md.A., Rahman, M.M., Rashid, M., 2015. Formulation and & In-Vitro Release Pattern Study of Gliclazide Matrix Tablet. *Pharmacol. Amp Pharm.* 06, 125–131.
- Ahammad, T., Hasan, M., Ahamed, I. and Islam, M.A., (2011) Effect of Granulation Technique and Drug-Polymer Rationon Release Kinetics of Gliclazide from Methocel K15M CR Matrix Tablet. *International Journal of PharmaceuticalSciences and Research*, 2, 1063-1068.
- Alhalmi, A., Altowairi, M., Saeed, O., Alzubaidi, N., Abdulmalik, W., n.d. SUSTAINED RELEASE MATRIX SYSTEM: AN OVERVIEW. *World J. Pharm. Pharm. Sci.* 7, 18.
- Ambrogi, V., Perioli, L., Ciarnelli, V., Nocchetti, M., Rossi, C., 2009. Effect of gliclazide immobilization into layered double hydroxide on drug release. *Eur. J. Pharm.*
- Badan Pengawas Obat dan Makanan Republik Indonesia. 2004. *Peraturan Kepala Badan Pengawas Obat dan Makanan tentang Pedoman Uji Bioekuivalensi*. Jakarta.
- Bezerra, K. de C., Pinto, E.C., Cabral, L.M., de Sousa, V.P., 2018. Development of a Dissolution Method for Gliclazide Modified-Release Tablets Using USP Apparatus 3 with *in Vitro–in Vivo* Correlation. *Chem. Pharm. Bull.* (Tokyo) 66, 701–707.
- Biswal, S., Sahoo, J., Murthy, P.N., Giradkar, R.P., Avari, J.G., 2008. Enhancement of Dissolution Rate of Gliclazide Using Solid Dispersions with Polyethylene Glycol 6000. *AAPS PharmSciTech* 9, 563–570.
- British Pharmacopeia. 2011. Her Majesty's Stasionery Office, London.
- Departemen Kesehatan Republik Indonesia. 2014. *Farmakope Indonesia*. Edisi V. Jakarta : Departemen Kesehatan Republik Indonesia.

- Dressman, J., Krämer, J., 2005. Pharmaceutical Dissolution Testing 424. Sarkar, A., Tiwari, A., Bhasin, P.S., Mitra, M., n.d. Pharmacological and Pharmaceutical Profile of Gliclazid: A Review. *J. Appl. Pharm. Sci.* 9.
- Duan, J.Z., Riviere, K., Marroum, P., 2011. In Vivo Bioequivalence and In Vitro Similarity Factor ( $f_2$ ) for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match? *Pharm. Res.* 28, 1144–1156.
- Edyaningrum, A., 2013. PERBANDINGAN MUTU FISIK DAN PROFIL DISOLUSI TABLET GLIBENKLAMID MERK DAGANG DAN GENERIK 18.
- Elsayed, T.M., Mandal, U.K., Kasmuri, A., 2015. Development of Generic Gliclazide 60 mg Modified Release Tablets Using Central Composite Design. *Lat. Am. J. Pharm.* 11.
- El Yahya, I.R., Abdassah, M., 2019. Review : Matriks Polimer yang Digunakan pada Tablet Sustained Release. *Farmasetikacom Online* 4, 78.
- Grbic, S., Parojcic, J., Ibric, S., Djuric, Z., 2011. In Vitro–In Vivo Correlation for Gliclazide Immediate-Release Tablets Based on Mechanistic Absorption Simulation. *AAPS PharmSciTech* 12, 165–171.
- FDA, 2000, Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, U. S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Rockville, 1-8.
- Fudholi, A., 2013. *Disolusi Dan Pelepasan Obat in Vitro*. Pustaka Pelajar, Yogyakarta.
- Islam, S., Dey, L.R., Shahriar, M., Dewan, I., Islam, S.A., 2013. Enhancement of Dissolution Rate of Gliclazide Using Solid Dispersions: Characterization and Dissolution Rate Comparison. *Bangladesh Pharm. J.* 16, 45–52.
- Jeyaprabha, P., Sudhamani, T., Mahendra, H., Ganesan, V., Senthil, S.P., 2010. FORMULATION AND EVALUATION OF GLICLAZIDE MODIFIED RELEASE TABLETS USING HYDROXYPROPYL CELLULOSE 6.

- Khattab, I.S., Nada, A., Zaghloul, A.-A., 2010. Physicochemical characterization of gliclazide–macrogol solid dispersion and tablets based on optimized dispersion. *Drug Dev. Ind. Pharm.* 36, 893–902.
- Krämer J, Grady LT, Gajendran J. Historical development of dissolution testing. In *Pharmaceutical dissolution testing*; Dressman J, Krämer J, Eds.; Taylor & Francis Group: Boca Raton, FL, 2005; 1–37.
- Lachman, L., Lieberman, H. dan Kanig, J., 1987. *The Theory and Practice of Industrial Pharmacy*, Varghese Publishing House, Dadar Bombay.
- Lu, Z., Yang, Y., Covington, R.-A., Bi, Y., Dürig, T., Fassihi, R., 2017. Amorphous-based controlled-release gliclazide matrix system. *AAPS PharmSciTech* 18, 1699–1709.
- McGavin, J.K., Perry, C.M., Goa, K.L., 2002. *Gliclazide Modified Release* 8.
- Mansour, H.F., F. Aly, U., 2015. In vitro evaluation and in vivo performance of lyophilized gliclazide. *Drug Dev. Ind. Pharm.* 41, 650–657.
- Nasif, H., Zaini, E., 2017. Uji Dissolusi Terbanding Tablet Metilprednisolon Generik Bermerek dan Generik Berlogo Dibandingkan Dengan Tablet Metilprednisolon Paten 19, 6.
- Sarkar, A., Tiwari, A., Bhasin, P.S., Mitra, M., n.d. Pharmacological and Pharmaceutical Profile of Gliclazide: A Review. *J. Appl. Pharm. Sci.* 9.
- Skripnik, K.K.S., Riekes, M.K., Pezzini, B.R., Cardoso, S.G., Stulzer, H.K., 2017. Investigation of the Dissolution Profile of Gliclazide Modified-Release Tablets Using Different Apparatuses and Dissolution Conditions. *AAPS PharmSciTech* 18, 1785–1794.
- Shargel, L., Wu-Pong, S. and Yu, B.C A., 2004. *Biofarmasetika dan Farmakokinetika Terapan Edisi Kelima*. Alih Bahasa: Fasich, B.S. Surabaya: Pusat Penerbitan dan Percetakan Universitas Airlangga
- Shargel, L & Andrew. 2012. *Applied Biopharmaceutics & Pharmacokinetics*. New York: McGraw-Hill Companies.
- Shavi, G.V., Kumar, A.R., Usha, Y.N., Armugam, K., Ranjan, O. prakash, Gijupalli, K., Pandey, S., Udupa, N., 2010. Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques. *Int. J. Drug Deliv.* 2, 49–57.

- Siregar, C., Wikarsa., S. 2010. Teknologi Farmasi Sediaan Tablet Dasar - Dasar Praktis. Jakarta : EGC
- Siswanto, A., Fudholi, A., Nugroho, A.K., Martono, S., 2014. Pengaruh Medium Disolusi Dan Penggunaan Sinker Terhadap Profil Disolusi Tablet Floating Aspirin 13.
- Suhesti, T.S., Rachmani, E.P.N., 2018. Disolusi Terbanding Tablet Asetaminofen Produk Generik Berlogo dan Produk Bermerek.
- The United States Pharmacopeia and National Formulary USP 25–NF 20; The United States Pharmacopeial Convention, Inc.: Rockville, MD.
- Toverud, E. L., Hartmann, K., & Håkonsen, H. (2015). A Systematic Review of Physicians' and Pharmacists' Perspectives on Generik Drug Use: What are the Global Challenges. *Applied health economics and health policy*, 13(1), 35-45.
- Vuletic,L., Khan, M.Z.I., Spoljaric, D., Radic,M dan Cizmek,B.C. 2018. Development of a Clinically Relevant Dissolution Method for Metaxalone ImmediateRelease Formulations Based on an IVIVC Model. *Pharm Res*, 35(8).
- Waghmode, S.S., Abhang, D.R., Patil,M.B., Gangarde, N.A., Patil,D.P., dan Ahire, S.N., 2012.Stomach Specific Drug DeliverySystem and Its in Vitro-in VivoEvaluation: A Review. *IJPSR*, 3:1593–1602.
- Yang, J.-F., Wei, G.-L., Lu, R., Liu, C.-X., Zheng, B.-Z., Feng, P., 2013. Bioavailability of Gliklazid Sustained Release Tablet in Healthy Volunteers 9.